LOAN AGREEMENTLoan Agreement • September 28th, 2018 • Arog Pharmaceuticals, Inc. • Pharmaceutical preparations • Texas
Contract Type FiledSeptember 28th, 2018 Company Industry JurisdictionTHIS LOAN AGREEMENT (this “Loan Agreement”) dated effective as of April 11, 2018 (the “Effective Date”) is made and executed by and between Jain Investments, LLC, a Texas limited liability company (the “Lender”) and Arog Pharmaceuticals, Inc., a Delaware corporation (the “Borrower”).
ASSET PURCHASE AGREEMENTAsset Purchase Agreement • September 28th, 2018 • Arog Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledSeptember 28th, 2018 Company Industry JurisdictionThis Asset Purchase Agreement (this “Agreement”) is made and entered into effective as of January 5, 2015 (the “Effective Date”), by and between Arog Pharmaceuticals, Inc., a Delaware corporation ( “Seller”), and Videra Pharmaceuticals, LLC a Delaware limited liability company ( “Buyer”). Seller and Buyer are sometimes referred to herein as the “Parties,” and each, a “Party.”
MASTER SERVICES AGREEMENTMaster Services Agreement • September 28th, 2018 • Arog Pharmaceuticals, Inc. • Pharmaceutical preparations • Texas
Contract Type FiledSeptember 28th, 2018 Company Industry JurisdictionThis Master Services Agreement (“Agreement”), is effective June 12, 2018 (the “Effective Date”), by and between Arog Pharmaceuticals, Inc., a Delaware corporation, having a principal place of business at 5420 LBJ Freeway, Suite 410, Dallas TX 75240 (“Recipient”), and Jain Investments, LLC,, a Texas limited liability company having a principal place of business at or address at 5420 LBJ Freeway, Suite 410, Dallas, TX 75240 (“Provider”). Recipient and Provider may be referred to herein individually as a “Party” or, collectively, as the “Parties.”
First Amendment to the January S, 2015, License Agreement between AROG Pharmaceuticals, Inc. and Videra Pharmaceuticals, LLCLicense Agreement • September 28th, 2018 • Arog Pharmaceuticals, Inc. • Pharmaceutical preparations
Contract Type FiledSeptember 28th, 2018 Company IndustryThis Amendment (“Amendment”), dated June 22, 2018, (the “Amendment Effective Date”) is made by and between AROG Pharmaceuticals, Inc., (hereinafter referred to as “Company”), with a place of business at 5420 LBJ Freeway, Ste. 410, Dallas, Texas 75240, United States, and Videra Pharmaceuticals, LLC (hereinafter referred to as “Licensee”), with a place of business at 5420 LBJ Freeway, Suite 410, Dallas, TX 75240, United States. Company and Licensee are each individually referred to herein as a “Party” and collectively as the “Parties.”
STOCK PURCHASE AND DEBT CONVERSION AGREEMENTStock Purchase and Debt Conversion Agreement • September 28th, 2018 • Arog Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledSeptember 28th, 2018 Company Industry JurisdictionThis Stock Purchase and Debt Conversion Agreement (the “Agreement”) is made and entered into as of January 31, 2017 (the “Effective Date”) by and between Arog Pharmaceuticals Inc., a Delaware corporation (the “Company”), and Jain Investments LLC, a Texas limited liability company (the “Purchaser”). Capitalized terms not otherwise defined herein shall have the meanings assigned thereto in the Company’s Bylaws adopted pursuant to the Company’s Agreement and Plan of Conversion, effective September 30, 2014 (the “Bylaws”).
LICENSE AGREEMENTLicense Agreement • September 28th, 2018 • Arog Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Contract Type FiledSeptember 28th, 2018 Company Industry Jurisdiction